Drug Trial Radar · NCT06461429
PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]
Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100,000
Planned (sponsor's estimate)
Start
Nov 1, 2025
Primary completion
Dec 31, 2050
Study completion Dec 31, 2050
Sponsor
- Lead sponsor
- University of MelbourneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Auckland, New Zealand; Monash University; The University of Western Australia; La Trobe University; The University of New South Wales; University of Tasmania; Menzies School of Health Research; University of Adelaide; University of Sydney; Mater Medical Research Institute
- First posted
- Jun 17, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PLATIPUS is an adaptive platform trial aimed at improving the health of infants born preterm (before 37 weeks' gestation). PLATIPUS will compare how different treatments and care provided to pregnant women and people at risk of preterm birth and infants born preterm affect infant health. The main questions PLATIPUS aims to answer are: 1. What effect/s do different treatments/care provided to pregnant women and people at risk of preterm birth have on the health of their infants? (Pregnancy domains) 2. What effect/s do different treatments/care given to infants born preterm have on their health ? (Neonatal domains). This registration record relates to the PLATIPUS Core (or 'master') protocol which provides guidance for the overall running of the trial. Additional appendices will outline the aims, questions, treatments, and activities for each separate research question (domain). Each Domain-Specific Appendix will be registered separately on ClinicalTrials.gov and will link to this record.
Conditions
- Preterm Birth
Interventions
ErythromycinDrug
Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Amoxicillin and ErythromycinDrug
Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
AzithromycinDrug
Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Caffeine citrate 20 mg/kg load and 10 mg/kg daily maintenance.Drug
Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Caffeine citrate 30 mg/kg load and 15 mg/kg daily maintenance.Drug
Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Caffeine citrate 40 mg/kg load and 20 mg/kg daily maintenanceDrug
Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who progress by at least one level higher on the PLATIPUS Ordinal Outcome ScaleTime frame: At any time prior to 42 weeks' postmenstrual age or first discharge home from hospital (whichever is earlier).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.